Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Efficient and Multiplexed Somatic Genome Editing with Cas12a Mice
[Nature Biomedical Engineering] Investigators generated transgenic mice with Cre-regulated and constitutive expression of enhanced Acidaminococcus sp. Cas12a, which robustly generates compound genotypes, including diverse cancers driven by inactivation of trios of tumour suppressor genes or an oncogenic translocation.
Intracerebroventricular Bivalent CAR T Cells Targeting EGFR and IL-13Rα2 in Recurrent Glioblastoma: A Phase I Trial
[Nature Medicine] Researchers reported the dose escalation and exploration phases of a Phase I trial investigating intracerebroventricular delivery of bivalent CAR T cells targeting epidermal growth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL-13Rα2), or CART-EGFR-IL13Rα2 cells, in patients with EGFR-amplified recurrent glioblastoma.
Secretion of a VEGF-Blocking scFv Enhances CAR T-Cell Potency
[Cancer Immunology Research] Investigators showed that CAR T cells from patients treated with FDA-approved CAR T-cell products express members of the VEGF signaling pathway and this expression is correlated with patient non-response.
Anti-Viral CD8 Central Memory Veto Cells As a New Platform for CAR T Cell Therapy
[Stem Cells Translational Medicine] Human anti-viral CD8 central memory veto T cells generated from CMV and EBV-positive donors were evaluated in a clinical trial at MD Anderson Cancer Centre.
Advances in Viral Vector-Based Delivery Systems for Gene Therapy: A Comprehensive Review
[3 Biotech] Investigators explore recent advancements in viral vector platforms, focusing on intracellular trafficking, transgene expression, and strategies to optimize vector design.
STEMCELL Technologies Announces Acquisition of Cellular Highways
[STEMCELL Technologies] STEMCELL Technologies announced the acquisition of Cellular Highways Ltd. Cellular Highways specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia with ANKTIVA®, the Cancer BioShield™ Platform, in Patients with Solid Tumors
[ImmunityBio, Inc.] ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherapy, radiation, or immunotherapy.
In Vivo Hemopoietic Stem Cell Gene Therapy Enabled by Postnatal Trafficking
[Nature] Scientists demonstrated that in vivo gene delivery to hematopoietic stem and progenitor cells after systemic lentiviral administration is enabled by the substantial trafficking of these cells from the liver to the bone marrow in newborn mice.
Remodeling Hypoxic TNBC Microenvironment Restores Antitumor Efficacy of Vγ9Vδ2 T Cell Therapy
[British Journal of Cancer] Data from TCGA, publicly available scRNA-seq datasets, and a series of experiments including flow cytometry, atomic force microscopy, confocal laser scanning microscopy, mouse model and others were applied to examine the functional heterogeneity of γδ T cells in TNBC, non-TNBC, and healthy individuals.
A TIM-3-Fc Decoy Secreted by Engineered T Cells Improves CD19 CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
[Blood] Investigators characterized the expression of immune checkpoint receptors and their ligands in leukemic blasts, T cells, and mesenchymal stromal cells from B-cell acute lymphoblastic leukemia bone marrow (BM) samples at diagnosis and relapse, comparing them with age-matched healthy BM controls.
Nanobody-Directed CEA-targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts
[Cancer Immunology Research] The authors used a sequentially tumor-selected antibody and antigen retrieval system to isolate a nanobody that directs CAR T cells to attack gastrointestinal tumor cells in preclinical mouse models.
T Cell Receptor Mimic CAR T Cells Targeting Cathepsin G Signal Peptide
[Leukemia] Researchers identified the HLA-A2-restricted, cathepsin G-derived signal peptide, CG1, as a promising immunotherapeutic target.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.